喉癌组织中PD-L1的表达及意义

目的:探讨程序性死亡配体-1(PD-L1)在喉癌及癌旁组织中的表达及临床意义。方法:采用免疫组织化学和Western-blotting技术分别检测31例喉癌组织和24例癌旁组织中PD-L1的蛋白表达水平及差异。结果:PD-L1在喉低、低中分化鳞状细胞癌中的表达明显高于高分化癌组织,前者PD-L1主要表达于血管,瘤细胞少见,后者血管常呈弱表达而局部瘤细胞呈阳性表达;PD-L1的表达与淋巴转移相关。癌旁组织中PD-L1表达明显低于癌组织,然其表达水平与其对应癌组织呈正相关。结论:PD-L1可能在喉癌特别是低及低中分化喉癌的发生、发展和(或)转移中起到一定作用,有望成为喉癌尤其是低、低中分化喉癌治疗的一个新靶点。

Expression and significance of PD-L1 in laryngocarcinoma

Objective:To study the expression of ligand 1 of programmed death-1(PD-L1) in human laryngocarcinoma tissues and peritumora l tissue and its potential significance to clinic.Method:Immunohistochemistry and Western-blotting were performed to assess the expression of PD-L1 at protein level and the differences in 31 cases of laryngocarcinoma tissue and 24 cases of paraneoplastic tissue.Result:Expression of PD-L1 was significantly higher in poorly and moderately differentiated larynx squamous carcinoma than that in well differentiated larynx squamous carcinoma.The expression of PD-L1 in the former was mainly in blood vessels while rarely in cancer cells,and the blood vessel of the latter displayed weakly positive while partial cancer cells showed positive;and the expression of PD-L1 was significantly correlated with lymphatic metastasis.Expression of PD-L1 in paraneoplastic tissues was significantly lower than that in cancer tissues but positively correlated to the expression level in the cancer tissues.Conclusion:PD-L1 may play a part in the development and/or metastasis of laryngocarcinoma,particularly in the bad differentiated;And it maybe a new target of immunotherapy for laryngocarcinoma,especially for the poorly and moderately differentiated.